"Comments raised by 'Using large language models to identify geriatric assessment domains in patients with advanced cancer: A feasibility study.'" [0.03%]
“利用大型语言模型识别晚期癌症患者老年综合评估领域的可行性研究”存在的问题及建议
Yohei Kishi,Anri Inumaru,Yurika Saito et al.
Yohei Kishi et al.
Management of older adults with colorectal cancer - The state-of-the-art in 2026 [0.03%]
2026年的结直肠癌老年患者管理现状及展望
Gabor Liposits,Thierry André,Thomas Aparicio et al.
Gabor Liposits et al.
Cognitive dysfunction associated with endocrine therapy and CDK4/6 inhibitors in breast cancer: A real-world analysis of the FDA Adverse Event Reporting System (FAERS) database [0.03%]
基于FDA不良事件报告系统数据库分析乳腺癌内分泌治疗及CDK4/6抑制剂相关认知功能障碍的现实世界研究
Dandan Fan,Yanan Wang,Junping Han et al.
Dandan Fan et al.
Introduction: Endocrine therapies (ETs) and CDK4/6 inhibitors are cornerstone treatments for hormone receptor-positive (HR+) breast cancer, but their association with cognitive dysfunction remains poorly characterized. Gi...
Role, impact, and feasibility of a comprehensive pharmacist medication review for patients in the older adult cancer clinic (OACC) at Princess Margaret Cancer Centre [0.03%]
多发于老年癌症中心患者的综合药学评估的角色、影响及可行性研究
Sabrina Mellor,Malgorzata Tyszka,Neha Pathak et al.
Sabrina Mellor et al.
Introduction: Older adults with cancer are at greater risk of experiencing drug therapy problems (DTPs), often related to multiple comorbidities, advanced age, and cancer treatments. Increasing evidence demonstrates the v...
Frailty, medical complexity, and inpatient outcomes in older adults with cancer: An evaluation of an embedded onco-geriatric service [0.03%]
脆弱性、医疗复杂性和老年癌症患者的住院结果：嵌入式肿瘤老年医学科评估
Shipra Verma,Prudence Wignall,Bhaskar Mandal et al.
Shipra Verma et al.
Prevalence of functional impairments in older, community-dwelling adults with and without a history of cancer: Analysis of wave 1 of the Irish longitudinal study on ageing (TILDA) [0.03%]
癌症史对社区中老年成年人身体功能衰退的影响：来自爱尔兰老龄化纵向研究（TILDA）第一阶段的分析
Maya K Johnson,Siobhan Scarlett,Ann Monaghan et al.
Maya K Johnson et al.
Introduction: Improvements in cancer survival are happening in the context of an ageing population who may experience age-related complications from cancer therapies and unique needs in cancer survivorship. The long-term ...
Interpreting patient-centred outcomes and safety in geriatric co-management [0.03%]
老年综合症治疗中以患者为中心的结果和安全性的解读
Ilyas Das,Aya Abukwaik,Louis J Koizia et al.
Ilyas Das et al.
Quality of life and function in younger and older women treated for non-metastatic breast cancer: Three or more years post primary treatment [0.03%]
年轻及老年女性治疗非转移性乳腺癌后三到三年以上的生存质量及功能状况
Karie Turley,Alexis C Wardell,Allison M Deal et al.
Karie Turley et al.
Introduction: Advances in breast cancer treatments have reduced acute toxicities, but there can be lingering side effects that impact quality of life (QoL) and function years after treatment completion. Understanding thes...
Machine learning models as a supporting tool to decide systemic therapy for older adults with cancer [0.03%]
机器学习模型作为决定癌症老年患者全身治疗的辅助工具
Gonzalo Navarrete,Gabriel Martínez,Claudio Barrientos et al.
Gonzalo Navarrete et al.
This manuscript is expected to be considered as a "Research Letter"; therefore, an Abstract is not mandatory. Keywords: ...
Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting [0.03%]
BRUIN CLL-321研究中患者的报告结果：一项在既往接受过cBTKi治疗的复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者中比较pirtobrutinib与依鲁替尼联合利妥昔单抗或苯达莫司汀联合利妥昔单抗的3期随机试验
Paolo Ghia,Davide Rossi,Emmanuelle Ferrant et al.
Paolo Ghia et al.
Introdcution: The phase 3, randomized trial BRUIN CLL-321 assessed the safety and efficacy of pirtobrutinib versus investigators choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR) in patients...